Liu Jiewei
Department of Psychiatry, Wuhan Mental Health Center, Wuhan, 430012, Hubei, China.
Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan, 430012, Hubei, China.
Eur Child Adolesc Psychiatry. 2025 Feb;34(2):721-728. doi: 10.1007/s00787-024-02517-4. Epub 2024 Jul 2.
Identification of changes in protein abundance for attention-deficit/hyperactivity disorder (ADHD) is important for potential disease mechanisms and therapeutic study for ADHD. In order to identify candidate proteins that confer risk for ADHD, a proteome-wide association study (PWAS) for ADHD was conducted by integrating two human brain proteome datasets and the ADHD genome-wide association study (GWAS) summary statistics released by the Psychiatric Genomics Consortium (PGC). A total of 11 risk proteins were identified as significant candidates that passed the bonferroni corrected proteome-wide significant (PWS) level. The predicted protein abundance level of LSM6, GMPPB, ICA1L and CISD2 are shown significantly associated with ADHD in both proteome datasets, highlighting their potential role in ADHD pathogenesis. A transcriptome-wide association study (TWAS) of ADHD was also conducted, and 13 genes with predicted expression changes related to ADHD were identified. GMPPB, ICA1L and NAT6 were supported by both TWAS and PWASs analysis. This study uncovers the predicted protein abundance changes that confer risk for ADHD and pinpoints a number of high-confidence protein candidates (e.g. LSM6, GMPPB, ICA1L, CISD2) for further functional exploration studies and drug development targeting these proteins.
识别注意力缺陷多动障碍(ADHD)患者蛋白质丰度的变化,对于了解潜在的疾病机制以及开展ADHD治疗研究具有重要意义。为了识别与ADHD风险相关的候选蛋白质,研究人员整合了两个人脑蛋白质组数据集以及精神基因组学联盟(PGC)发布的ADHD全基因组关联研究(GWAS)汇总统计数据,开展了一项针对ADHD的全蛋白质组关联研究(PWAS)。共有11种风险蛋白质被确定为通过了邦费罗尼校正的全蛋白质组显著(PWS)水平的显著候选蛋白。在两个蛋白质组数据集中,LSM6、GMPPB、ICA1L和CISD2的预测蛋白质丰度水平均显示与ADHD显著相关,突出了它们在ADHD发病机制中的潜在作用。研究人员还开展了一项ADHD的全转录组关联研究(TWAS),并确定了13个与ADHD相关的预测表达变化的基因。GMPPB、ICA1L和NAT6在TWAS和PWAS分析中均得到支持。这项研究揭示了与ADHD风险相关的预测蛋白质丰度变化,并确定了一些高可信度的蛋白质候选物(如LSM6、GMPPB、ICA1L、CISD2),用于进一步的功能探索研究以及针对这些蛋白质的药物开发。